表紙
市場調査レポート

ProMetic Life Sciences Inc. : 製品パイプライン分析

ProMetic Life Sciences Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 203736
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
ProMetic Life Sciences Inc. : 製品パイプライン分析 ProMetic Life Sciences Inc. - Product Pipeline Review - 2015
出版日: 2015年08月26日 ページ情報: 英文 42 Pages
概要

ProMetic Life Sciences Inc. はバイオセパレーション技術、血漿由来治療、低分子薬剤を専門としたバイオ製薬会社です。

当レポートでは、Synthon BVにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを提供しています。ひと

ProMetic Life Sciences Inc.の基本情報

ProMetic Life Sciences Inc.の概要

  • 主要情報
  • 企業情報

ProMetic Life Sciences Inc.:R&Dの概要

  • 主な治療範囲

ProMetic Life Sciences Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

ProMetic Life Sciences Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

ProMetic Life Sciences Inc.:薬剤プロファイル

  • ヒト免疫グロブリン
  • PBI-1402
  • PBI-4050
  • ヒトプラスミノーゲン
  • α-1 ヒトプロティナーゼ阻害剤
  • PBI-0110
  • PBI-1393
  • PBI-1522
  • PBI-1668
  • PBI-1737
  • PBI-4419
  • PBI-4494
  • PBI-4547

ProMetic Life Sciences Inc.:パイプライン分析

  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ProMetic Life Sciences Inc.:最近のパイプライン動向

ProMetic Life Sciences Inc.:休止中のプロジェクト

ProMetic Life Sciences Inc.:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07431CDB

Summary

Global Markets Direct's, 'ProMetic Life Sciences Inc. - Product Pipeline Review - 2015', provides an overview of the ProMetic Life Sciences Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ProMetic Life Sciences Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ProMetic Life Sciences Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ProMetic Life Sciences Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ProMetic Life Sciences Inc.'s pipeline products

Reasons to buy

  • Evaluate ProMetic Life Sciences Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ProMetic Life Sciences Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ProMetic Life Sciences Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ProMetic Life Sciences Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ProMetic Life Sciences Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ProMetic Life Sciences Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ProMetic Life Sciences Inc. Snapshot
    • ProMetic Life Sciences Inc. Overview
    • Key Information
    • Key Facts
  • ProMetic Life Sciences Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • ProMetic Life Sciences Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ProMetic Life Sciences Inc. - Pipeline Products Glance
    • ProMetic Life Sciences Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ProMetic Life Sciences Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ProMetic Life Sciences Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • ProMetic Life Sciences Inc. - Drug Profiles
    • immune globulin (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-1402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plasminogen (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alpha-1 proteinase inhibitor (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-0110
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-1393
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-1522
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-1668
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-1737
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4419
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4494
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4547
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ProMetic Life Sciences Inc. - Pipeline Analysis
    • ProMetic Life Sciences Inc. - Pipeline Products by Target
    • ProMetic Life Sciences Inc. - Pipeline Products by Route of Administration
    • ProMetic Life Sciences Inc. - Pipeline Products by Molecule Type
    • ProMetic Life Sciences Inc. - Pipeline Products by Mechanism of Action
  • ProMetic Life Sciences Inc. - Recent Pipeline Updates
  • ProMetic Life Sciences Inc. - Dormant Projects
  • ProMetic Life Sciences Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ProMetic Life Sciences Inc., Key Information
  • ProMetic Life Sciences Inc., Key Facts
  • ProMetic Life Sciences Inc. - Pipeline by Indication, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Stage of Development, 2015
  • ProMetic Life Sciences Inc. - Monotherapy Products in Pipeline, 2015
  • ProMetic Life Sciences Inc. - Phase III, 2015
  • ProMetic Life Sciences Inc. - Phase II, 2015
  • ProMetic Life Sciences Inc. - Phase I, 2015
  • ProMetic Life Sciences Inc. - Preclinical, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Target, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Route of Administration, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Molecule Type, 2015
  • ProMetic Life Sciences Inc. - Pipeline Products by Mechanism of Action, 2015
  • ProMetic Life Sciences Inc. - Recent Pipeline Updates, 2015
  • ProMetic Life Sciences Inc. - Dormant Developmental Projects,2015
  • ProMetic Life Sciences Inc., Other Locations
  • ProMetic Life Sciences Inc., Subsidiaries

List of Figures

  • ProMetic Life Sciences Inc. - Pipeline by Top 10 Indication, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Stage of Development, 2015
  • ProMetic Life Sciences Inc. - Monotherapy Products in Pipeline, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Top 10 Target, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Top 10 Route of Administration, 2015
  • ProMetic Life Sciences Inc. - Pipeline by Top 10 Molecule Type, 2015
  • ProMetic Life Sciences Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top